Sentences with phrase «growth factor production»

Too much growth factor production by some cancer cells helps them grow quickly.

The mechanism by which human neural progenitor cells exert their effects within the retina is not wholly clear, but is likely due in part to growth factor production [39] and possibly also to the manifestation of some RPE - like properties.

Protein secretion does not always mirror mRNA levels and most workers in the field would adopt a more conservative profile of cytokine and growth factor production by MSC.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

Such risks, uncertainties and other factors include, without limitation: (1) the effect of economic conditions in the industries and markets in which United Technologies and Rockwell Collins operate in the U.S. and globally and any changes therein, including financial market conditions, fluctuations in commodity prices, interest rates and foreign currency exchange rates, levels of end market demand in construction and in both the commercial and defense segments of the aerospace industry, levels of air travel, financial condition of commercial airlines, the impact of weather conditions and natural disasters and the financial condition of our customers and suppliers; (2) challenges in the development, production, delivery, support, performance and realization of the anticipated benefits of advanced technologies and new products and services; (3) the scope, nature, impact or timing of acquisition and divestiture or restructuring activity, including the pending acquisition of Rockwell Collins, including among other things integration of acquired businesses into United Technologies» existing businesses and realization of synergies and opportunities for growth and innovation; (4) future timing and levels of indebtedness, including indebtedness expected to be incurred by United Technologies in connection with the pending Rockwell Collins acquisition, and capital spending and research and development spending, including in connection with the pending Rockwell Collins acquisition; (5) future availability of credit and factors that may affect such availability, including credit market conditions and our capital structure; (6) the timing and scope of future repurchases of United Technologies» common stock, which may be suspended at any time due to various factors, including market conditions and the level of other investing activities and uses of cash, including in connection with the proposed acquisition of Rockwell; (7) delays and disruption in delivery of materials and services from suppliers; (8) company and customer - directed cost reduction efforts and restructuring costs and savings and other consequences thereof; (9) new business and investment opportunities; (10) our ability to realize the intended benefits of organizational changes; (11) the anticipated benefits of diversification and balance of operations across product lines, regions and industries; (12) the outcome of legal proceedings, investigations and other contingencies; (13) pension plan assumptions and future contributions; (14) the impact of the negotiation of collective bargaining agreements and labor disputes; (15) the effect of changes in political conditions in the U.S. and other countries in which United Technologies and Rockwell Collins operate, including the effect of changes in U.S. trade policies or the U.K.'s pending withdrawal from the EU, on general market conditions, global trade policies and currency exchange rates in the near term and beyond; (16) the effect of changes in tax (including U.S. tax reform enacted on December 22, 2017, which is commonly referred to as the Tax Cuts and Jobs Act of 2017), environmental, regulatory (including among other things import / export) and other laws and regulations in the U.S. and other countries in which United Technologies and Rockwell Collins operate; (17) the ability of United Technologies and Rockwell Collins to receive the required regulatory approvals (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the merger) and to satisfy the other conditions to the closing of the pending acquisition on a timely basis or at all; (18) the occurrence of events that may give rise to a right of one or both of United Technologies or Rockwell Collins to terminate the merger agreement, including in circumstances that might require Rockwell Collins to pay a termination fee of $ 695 million to United Technologies or $ 50 million of expense reimbursement; (19) negative effects of the announcement or the completion of the merger on the market price of United Technologies» and / or Rockwell Collins» common stock and / or on their respective financial performance; (20) risks related to Rockwell Collins and United Technologies being restricted in their operation of their businesses while the merger agreement is in effect; (21) risks relating to the value of the United Technologies» shares to be issued in connection with the pending Rockwell acquisition, significant merger costs and / or unknown liabilities; (22) risks associated with third party contracts containing consent and / or other provisions that may be triggered by the Rockwell merger agreement; (23) risks associated with merger - related litigation or appraisal proceedings; and (24) the ability of United Technologies and Rockwell Collins, or the combined company, to retain and hire key personnel.

Moody's also expects nickel and cobalt supplies to be insufficient to support growing demand for battery production, becoming another constraining factor on near term BEV growth.

The looming supply growth is mostly due to two factors: the scheduled end of OPEC / non-OPEC production cuts in March and US shale production, including NGLs, «growing like crazy,» said New York - based Mike Wittner, managing director and global head of oil research at Societe Generale.

Furthermore, guidance for total production doesn't factor in much growth, and the low end of the range would in fact be a reduction in output.

As a result of these factors, Pioneer expects production growth to come in at the low end of its 15 % - to - 18 % guidance range for the year, while oil as a percentage of total production will be 58 % instead of the 62 % it expected.

This factor took a back seat during the oil price rally in recent months, but with production growth of nearly 850,000 barrels per day since late in the summer, U.S. oil producers have demonstrated how aggressive they can be in a rising price environment.

Studies show that a Ketogenic Diet can increase the production of brain derived neurotropic factor (BDNF), an anti-inflammatory protein that promotes the growth of nerves.1

There is room for growth in that market but a limiting factor will be how much we can increase production,» he said.

Trends and factors driving organic growth suggest the outlook for organic production and sale until 2010 as well as possible implications on commodity trade and land use.

The data from this study indicate that when moms are given breastfeeding support, milk production is not a limiting factor and provides enough calories for normal growth, even in 6 - month - old infants.

Dr Akoto said the smuggling of cocoa and its subsidised inputs into neighbouring countries as a direct consequence of the input distribution system and the product pricing policies of the government, as well as the refusal of the government to pay annual production bonuses to farmers, was the other factor inhibiting growth in the cocoa sub-sector.

GHRH boosts production of growth hormone and insulin - like growth factor - 1, both of which build muscle.

But recent research has linked their long term use to various unwanted effects, including pneumonia, heart attack, and bone fracture, they point out, adding that PPIs are known to stimulate the production of gastrin, a powerful growth factor.

«Considering the large portion of the green industry involved with growing plants in containers and the importance of understanding the physiology and morphology of roots, the factors that influence root growth in container production should be continually investigated,» they wrote.

This happens because the loss of blood flow in a vessel causes the local oxygen level to drop, which stimulates local production of vascular endothelial growth factor, or VEGF, a protein which in most tissues causes the growth of new blood vessels to repair damage.

These long - lived worms had mutations that decreased the production of a protein known as insulinlike growth factor 1 (IGF - 1), which helps drive cellular growth and division.

Demonstrating Cpf1's noticeable specificity, another research team from the same IBS Center succeeded in bringing Cpf1 RNP - mediated mutations into mouse embryos: The researchers targeted Foxn1 (a transcription factor that regulates the immune system, including the growth of skin hairs), as well as Tyrosinase (an enzyme that catalyzes the production of melanin, a natural pigment that determines the color of skin).

The new test instead looks for hGH's knock - on effects in the body — namely, increased production of insulin - like growth factor 1 (IGF - 1) and a substance called P3NP.

Abnormal and uncontrolled production of this class of proteins, known as transcription factors, allow for cells to bypass growth control mechanisms and to develop characteristics necessary for invading surrounding tissues.

«BDNF is a basic growth factor and it's related to neurogenesis, the production of new neurons,» Barbey said.

It is this factor that will limit future production growth.

So Hoffman is now looking for leads among genes controlling the production of molecules called growth factors, which regulate cell growth and division.

Compared to their unmodified counterparts, the growth factors containing the PIGF - 2 sequence resulted in much faster wound closing and production of granulation tissue, and also led to a more pronounced new blood vessel formation, which is essential in sustaining the latter.

The scientists in Augustin's laboratory consequently pursued preclinical tumor therapy experiments, which were aimed at not just blocking angiogenesis, but to also suppress the production of tumor - promoting growth factors in endothelial cells.

These analyses showed that Angiopoietin - 2 is not just affecting angiogenesis, but controls at the same time the production of tumor promoting growth factors in endothelial cells.

In addition to providing a platform for studying the processes that regulate platelet production and related diseases, the researchers hope the platelets produced can be used as a source of growth factors for wound healing in regenerative medicine, including healing of ulcers and burns, and stimulation of bone tissue regeneration in dentistry and maxillofacial plastic surgery.

As a factor of production, technology produces wealth and produces more technological progress, enabling a virtuous cycle of exponential growth (11, 12).

Bovine growth hormone is also known to stimulate the production of insulinlike growth factor 1 (IGF1) by the liver; some studies have shown that high levels of IGF1 in the bloodstream may heighten the risk of prostate and breast cancers as well as a woman's chance of conceiving twins.

In other words, during the exponential growth that we have experienced, something produced must itself have been a factor of production.

A relatively fixed factor of production such as land (today we would include all natural resources) can not produce positive feedback for exponential growth.

These include lipid lowering; protection from oxidative stress and inflammation; modification of growth factors that can promote cancer; inhibition of nutrient sensing pathways by amino acid restriction and gut microbiota - mediated production of metabolites.

This happens because the loss of blood flow in a blood vessel causes the local oxygen level to drop, which stimulates local production of vascular endothelial growth factor, or VEGF, a protein that in most tissues causes the growth of new blood vessels to repair damage.

Glucose regulated protein 94 is required for muscle differentiation through its control of the autocrine production of insulin - like growth factors.

Hepatitis C Virus Regulates Transforming Growth Factor [beta] 1 Production Through the Generation of Reactive Oxygen Species in a Nuclear Factor [kappa] B - Dependent Manner.

A major aspect of this process is the production of multiple angiogenic cytokines and growth factors in response to hypoxia / ischemia, which is mediated by the transcription factor HIF - 1 (hypoxia - inducible factor 1).

The result is an accumulation of senescent cells, which causes inflammation, tissue degradation and the production of growth factors that alter the tissue microenvironment, leading to disease.

Processes like growth arrest are activated and others, like Initiation factor, the starting process of protein production, are dramatically deactivated.

Other factors that have significantly contributed to reduced U.S. carbon emissions are the recent new growth in domestic natural gas production - consumption and EPA regulations that have restricted new coal power plant construction.

Prior to transplantation, we analyzed the in vitro production of specific growth factors by unmodified hNPCctx and by hNPCctx transduced with a lentiviral gene construct designed to constitutively express GDNF (hNPCctx - GDNF)[11], [44].

Researchers find that Insulin - like growth factor / Insulin - mediated induction of mesodermal differentiation aids the production of cardiac progenitor cells from embryonic stem cells towards a strategy to boost cardiac cell production.

Inhibition of growth, production of insulin - like growth factor - II (IGFII), and expression of IGF - II mRNA of human cancer cell lines by antagonistic analogs of growth hormone - releasing hormone in vitro.

Furthermore, we found that human IL - 15 mediated insulin - like growth factor - 1 production in CD215 + myeloid cells and blocking IGF - 1 reduced the tumor - promoting effect of IL - 15.

Even more profound was a drop in insulinlike growth factor 1 (IGF - 1), which is a biomarker for cancer growth, and an increase in stem cell production, which is a marker for regeneration of cells.

Other nootropics are even capable of stimulating the production of nerve growth factor where the protein synthesis ultimately results in brain cell growth, especially in the nerve cells» dendrites which enable the communication of electric impulses throughout the central nervous system.

Creatine's ability to increase muscular hypertrophy is derived largely from the fact that it is able to trigger creation of new muscle cells, increase protein synthesis in the muscles and decrease the production of myostatin which depletes muscle tissue, while at the same time increase the release of particular hormones that promote muscle building like IGF - 1 (Insulin Growth - like Factor) and testosterone.

This feeding cycle stimulates the production of cellular factors such as Cyclic AMP or GMP, which stimulate hormone synthesis and fat burning during the day, as well as protein synthesis and growth during the night, respectively.